Clinical Trial Details
| Trial ID: | L2438 |
| Source ID: | NCT00946257 |
| Associated Drug: | Otelixizumab |
| Title: | Subcutaneous Administration of Otelixizumab to T1DM Patients |
| Acronym: | RAO112438 |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 1 |
| Interventions: | DRUG: Otelixizumab |
| Outcome Measures: | Primary: Safety and tolerability after a single dose of otelixizumab in T1DM patients, 21 days | |
| Sponsor/Collaborators: | Sponsor: GlaxoSmithKline |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 33 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT |
| Start Date: | 2009-07-08 |
| Completion Date: | 2013-06-25 |
| Results First Posted: | |
| Last Update Posted: | 2017-06-01 |
| Locations: | GSK Investigational Site, Brussels, 1090, Belgium|GSK Investigational Site, Bruxelles, 1070, Belgium|GSK Investigational Site, Gent, 9000, Belgium|GSK Investigational Site, Leuven, 3000, Belgium|GSK Investigational Site, Liège, 4000, Belgium|GSK Investigational Site, Merksem, 2170, Belgium |
| URL: | https://clinicaltrials.gov/show/NCT00946257 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|